This funding will support the development and commercialization of our supervised AI-driven platform aimed at enhancing Deep Brain Stimulation (DBS) procedures for Parkinson’s Disease. The investment will help us expand globally, particularly in Europe and the US, and continue our innovations in neurosurgery.
Read the full article in French here.
An English translation by Google is available here.
Challenges underscores the significance of RebrAIn's technology in enhancing the precision and efficiency of deep brain stimulation (DBS) surgeries. By leveraging machine learning algorithms trained on extensive clinical data, RebrAIn's software assists neurosurgeons...
The Strategic Importance of This Tender This success marks a major strategic turning point for RebrAIn, as the Resah procurement center plays a key role in the public healthcare sector in France. By enabling the member hospitals to choose the most effective...
Recently, the Focused Ultrasound Foundation highlighted RebrAIn's success in obtaining its second FDA 510(k) approval - which extends the capabilities of its OptimMRI software to include new machine learning models for lesioning treatment of Essential Tremor, thereby...